menu
    • menu
    [{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Key Oncologics"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Not Applicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Onko Kocsel Pharmaceutical"},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Adium Pharma"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar \/ TOYO Pharmaceutical"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Trabectedin

    Menu

    Trabectedin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ever Pharma

                            Austria
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EVER Pharma gains EU Marketing Authorization for Trabectedin

                            Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.

                            Brand Name : Trabectedin EVER Pharma

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2024

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Ever Pharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmamar Receives US$10 Million Milestone Payment from Janssen

                            Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valeo Pharma Commences Yondelis® Commercialization in Canada

                            Details : Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with unresectable or metastatic liposarcoma or leiomyo...

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 06, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Specialised Therapeutics

                            Australia arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Global Sarcoma Therapy Now Approved for New Zealand Patients

                            Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 17, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmamar Receives US$10 Million Milestone Payment from Janssen

                            Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Natco Pharma

                            India arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Natco Pharma

                            India arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Natco Pharma Gets Tentative Approval for Yondelis Generic

                            Details : Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

                            Brand Name : Yondelis-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Specialised Therapeutics

                            Australia arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GLOBAL Sarcoma Therapy Now Approved for Australian Patients

                            Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-con...

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 23, 2021

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : STADA Arzneimittel

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PharmaMar and STADA Sign Agreement to Commercialize Yondelis® (trabectedin) in the MENA Region

                            Details : PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries for the treatment of soft tissue sarcoma and relaps...

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 17, 2020

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : STADA Arzneimittel

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Onko Kocsel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis® in Turkey

                            Details : Trabectedin is currently provided by Janssen to patients in Turkey for the treatment of Soft Tissue Sarcoma and, through this license, Onko will also pursue regulatory approval for the indication of relapsed ovarian cancer.

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 10, 2020

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Onko Kocsel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Adium Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis® in Latin America

                            Details : Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.

                            Brand Name : Yondelis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 27, 2020

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Adium Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth